Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Maintenance therapy for chronic hepatitis C].

Christian Trépo1, Anne-Marie Marion-Audibert, Didier Samuel

  • 1Service d'Hépato-Gastro-entérologie, Hôpital de l'Hôtel-Dieu & Unité INSERM U871, 1 place de l'Hôpital, 69288 Lyon cedex 02. christian.trepo@chu-lyon.fr

Gastroenterologie Clinique Et Biologique
|October 30, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA Cohort.

Cancers·2022
Same author

Management of Patients with Pancreatic Ductal Adenocarcinoma in the Real-Life Setting: Lessons from the French National Hospital Database.

Cancers·2021
Same author

The 2020 Nobel prize of Medicine for three hepatitis C discovery pioneers: a medical history milestone.

Clinics and research in hepatology and gastroenterology·2021
Same author

Hepatitis C (HCV) therapy for HCV mono-infected and HIV-HCV co-infected individuals living in Nepal.

PLoS neglected tropical diseases·2020
Same author

Perinatal hepatitis B virus transmission in Lao PDR: A prospective cohort study.

PloS one·2019
Same author

Non-F HBV/HDV-3 coinfection is associated with severe liver disease in Western Brazilian Amazon.

Journal of medical virology·2019
Same journal

[Not Available].

Gastroenterologie clinique et biologique·2014
Same journal

[Not Available].

Gastroenterologie clinique et biologique·2014
Same journal

[Not Available].

Gastroenterologie clinique et biologique·2014
Same journal

[Not Available].

Gastroenterologie clinique et biologique·2014
Same journal

[Not Available].

Gastroenterologie clinique et biologique·2014
Same journal

[Not Available].

Gastroenterologie clinique et biologique·2014
See all related articles

Even if hepatitis C (HCV) therapy fails, most patients show histological improvement. Maintenance therapy aims to reduce liver fibrosis progression and complications, especially with new treatments emerging.

Area of Science:

  • Hepatology
  • Virology
  • Gastroenterology

Context:

  • Chronic hepatitis C (HCV) therapy currently achieves a 60% sustained virological response rate.
  • HCV infection eradication failure does not negate therapeutic benefits; most patients exhibit biochemical and histological improvements.
  • Maintenance therapy is crucial for managing patients with advanced liver disease and those who do not achieve a complete virological response.

Purpose:

  • To evaluate the role and efficacy of maintenance therapy in preventing fibrosis progression and complications in chronic hepatitis C patients.
  • To analyze long-term outcomes of maintenance therapy in patients with advanced liver disease.
  • To assess the impact of interferon therapy on hepatocellular carcinoma (HCC) incidence.

Summary:

Related Experiment Videos

  • Meta-analysis of pivotal trials indicates 40% of patients failing to clear HCV showed histological improvement.
  • Long-term studies (HALT-C, COPILOT, EPIC 3) in advanced patients suggest maintenance therapy benefits.
  • Interim COPILOT data show low-dose peg-interferon reduced complication endpoints compared to placebo/colchicine.
  • Studies indicate long-term interferon therapy may reduce hepatocellular carcinoma (HCC) incidence.

    • Impact:

    • Maintenance therapy can mitigate fibrosis progression and reduce complications in chronic hepatitis C patients.
    • Findings support continued therapeutic strategies to prevent irreversible liver damage while awaiting new curative treatments.
    • Understanding the benefits of maintenance therapy is critical for patient management, particularly in the context of evolving HCV treatment landscapes.